Page last updated: 2024-11-13

enfumafungin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

enfumafungin: from endophytic Hormonema species; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

enfumafungin : A triterpene glycoside and hemiacetal isolated from a fermentation of Hormonema sp. and which specifically inhibits glucan synthesis in fungal cells. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID25229651
CHEMBL ID2165734
CHEBI ID61749
MeSH IDM0381199

Synonyms (11)

Synonym
enfumafungin
CHEBI:61749 ,
(1s,2r,3r,4ar,6as,7r,8r,10ar,10br,12as)-3-acetoxy-2-(beta-d-glucopyranosyloxy)-13-hydroxy-1,6a,8,10a-tetramethyl-8-[(2r)-3-methylbutan-2-yl]-1,3,4,6,6a,7,8,9,10,10a,10b,11,12,12a-tetradecahydro-2h-1,4a-(methanooxymethano)chrysene-7-carboxylic acid
CHEMBL2165734
Q27131364
260979-95-1
F82803
MS-31195
CS-0146081
HY-N8537
(1r,5s,6r,7r,10r,11r,14s,15s,20r,21r)-20-acetyloxy-18-hydroxy-5,7,10,15-tetramethyl-7-[(2r)-3-methylbutan-2-yl]-21-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-17-oxapentacyclo[13.3.3.01,14.02,11.05,10]henicos-2-ene-6-carboxylic acid

Research Excerpts

Overview

Efumafungin is a glycosylated fernene-type triterpenoid. It is produced by the fungus Hormonema carpetanum.

ExcerptReferenceRelevance
"Enfumafungin is a glycosylated fernene-type triterpenoid produced by the fungus Hormonema carpetanum. "( Enfumafungin synthase represents a novel lineage of fungal triterpene cyclases.
An, Z; Bills, GF; Chen, L; Cox, RJ; Kuhnert, E; Lan, N; Li, Y; Yokoyama, K; Yue, Q, 2018
)
3.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antifungal agentAn antimicrobial agent that destroys fungi by suppressing their ability to grow or reproduce.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
triterpenoid saponinA terpene glycoside in which the terpene moiety is a triterpenoid.
monosaccharide derivativeA carbohydrate derivative that is formally obtained from a monosaccharide.
lactolCyclic hemiacetals formed by intramolecular addition of a hydroxy group to an aldehydic or ketonic carbonyl group. They are thus 1-oxacycloalkan-2-ols or unsaturated analogues.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID1717511Antifungal activity against Candida glabrata CLY574 incubated for 24 hrs by liquid microdilution assay2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Recent Progress in the Discovery of Antifungal Agents Targeting the Cell Wall.
AID1717515Antifungal activity against Aspergillus fumigatus MF5668 assessed as inhibition of normal hyphal growth2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Recent Progress in the Discovery of Antifungal Agents Targeting the Cell Wall.
AID1717497Antifungal activity against Cryptococcus neoformans MY2061 incubated for 24 hrs by liquid microdilution assay2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Recent Progress in the Discovery of Antifungal Agents Targeting the Cell Wall.
AID1717510Antifungal activity against Candida albicans MY2301 incubated for 24 hrs by liquid microdilution assay2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Recent Progress in the Discovery of Antifungal Agents Targeting the Cell Wall.
AID1717512Antifungal activity against Candida glabrata MY1381 incubated for 24 hrs by liquid microdilution assay2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Recent Progress in the Discovery of Antifungal Agents Targeting the Cell Wall.
AID1717514Antifungal activity against Candida guilliermondii CLY346 incubated for 24 hrs by liquid microdilution assay2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Recent Progress in the Discovery of Antifungal Agents Targeting the Cell Wall.
AID1717496Antifungal activity against Cryptococcus neoformans MY2062 incubated for 24 hrs by liquid microdilution assay2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Recent Progress in the Discovery of Antifungal Agents Targeting the Cell Wall.
AID1717508Inhibition of Candida albicans MY1055 1,3-beta-D-glucan synthase assessed as reduction in glucan synthesis by measuring decrease in incorporation of [14C]glucose preincubated for 30 mins followed by pulse-labelling with [U-14C]D-glucose for 30 mins by aut2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Recent Progress in the Discovery of Antifungal Agents Targeting the Cell Wall.
AID1717705Antifungal activity against Candida albicans2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Recent Progress in the Discovery of Antifungal Agents Targeting the Cell Wall.
AID700191Antifungal activity against Candida albicans MY1055 after 24 hrs by NCCLS microdilution method2012Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22
Synthesis and biological evaluation of antifungal derivatives of enfumafungin as orally bioavailable inhibitors of β-1,3-glucan synthase.
AID1717498Antifungal activity against Aspergillus flavus MF383 incubated for 24 hrs by liquid microdilution assay2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Recent Progress in the Discovery of Antifungal Agents Targeting the Cell Wall.
AID1717513Antifungal activity against Candida guilliermondii CLY308 incubated for 24 hrs by liquid microdilution assay2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Recent Progress in the Discovery of Antifungal Agents Targeting the Cell Wall.
AID700192Inhibition of Candida albicans MY1055 beta-1,3-glucan synthase assessed as [3H]UDPG incorporation after 2 hrs2012Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22
Synthesis and biological evaluation of antifungal derivatives of enfumafungin as orally bioavailable inhibitors of β-1,3-glucan synthase.
AID1717509Antifungal activity against Candida albicans MY1055 incubated for 24 hrs by liquid microdilution assay2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Recent Progress in the Discovery of Antifungal Agents Targeting the Cell Wall.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (16.67)29.6817
2010's7 (58.33)24.3611
2020's3 (25.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.25 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index5.63 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (8.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (91.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]